Literature DB >> 22037132

Episode length and mixed features as predictors of ECT nonresponse in patients with medication-resistant major depression.

G Perugi1, P Medda, S Zanello, C Toni, G B Cassano.   

Abstract

OBJECTIVES: This study aimed to ascertain predictors of nonresponse to electroconvulsive therapy (ECT) in a large sample of major depressive patients resistant to pharmacologic treatment.
METHODS: A total of 208 depressive patients (31 with major depression [UP], 101 with bipolar disorder II [BP II], and 76 with bipolar disorder I [BP I] according to DSM-IV criteria) were included in the study and treated with bilateral ECT on a twice-a-week schedule. The patients were assessed before (baseline) and a week after the ECT course (final score) using the Hamilton Rating Scale for Depression-17 items (HAM-D-17), the Young Mania Rating Scale (YMRS), the Brief Psychiatric Rating Scale (BPRS), and the Clinical Global Improvement (CGI). Responders were defined as those patients with a reduction of at least 50% in HAM-D-17 score and a rating of 2 ("much improved") or 1 ("very much improved") in the CGI-Improvement subscale.
RESULTS: At the end of the ECT course, 152 patients (64%) were classified as responders and 56 patients (36%) were classified as nonresponders. On backward stepwise logistic regression, bipolar subtype (odds ratio [OR]=17.85; 95% confidence level [CL]=1.786-178.407), higher mean baseline YMRS scores (OR=1.094; 95% CL=1.025-1.166), lower mean baseline HAM-D-17 scores (OR=0.928; 95% CL=0.860-1.002), and length of current episode (OR=1.047; 95% CL=1.009-1.086) were identified as statistically significant predictors of nonresponse.
CONCLUSIONS: ECT was an effective treatment for approximately two-thirds of the patients with medication-resistant depression who were included in this study. ECT nonresponse was associated with bipolar subtype, presence of manic symptoms during depression, slightly less severe depressive symptomatology, and protracted duration of the episode.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22037132     DOI: 10.1016/j.brs.2011.02.003

Source DB:  PubMed          Journal:  Brain Stimul        ISSN: 1876-4754            Impact factor:   8.955


  8 in total

1.  Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial.

Authors:  Manish K Jha; Ashley L Malchow; Bruce D Grannemann; A John Rush; Madhukar H Trivedi
Journal:  Neuropsychopharmacology       Date:  2018-08-15       Impact factor: 7.853

2.  Naturalistic Study on the Effects of Electroconvulsive Therapy (ECT) on Depressive Symptoms.

Authors:  Sarah A Goegan; Gary M Hasey; Jelena P King; Bruno J Losier; Peter J Bieling; Margaret C McKinnon; Heather E McNeely
Journal:  Can J Psychiatry       Date:  2021-12-13       Impact factor: 5.321

3.  Similar clinical improvement of depression using 0.5-ms and 1-ms pulse widths in bilateral electroconvulsive therapy.

Authors:  Aida de Arriba-Arnau; Virginia Soria; Neus Salvat-Pujol; José M Menchón; Mikel Urretavizcaya
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-12-13       Impact factor: 5.270

4.  Treatment-resistant depression: therapeutic trends, challenges, and future directions.

Authors:  Khalid Saad Al-Harbi
Journal:  Patient Prefer Adherence       Date:  2012-05-01       Impact factor: 2.711

5.  Sensory Processing Disorders are Associated with Duration of Current Episode and Severity of Side Effects.

Authors:  Gianluca Serafini; Batya Engel-Yeger; Gustavo H Vazquez; Maurizio Pompili; Mario Amore
Journal:  Psychiatry Investig       Date:  2016-12-29       Impact factor: 2.505

6.  Blood homocysteine concentration and mood disorders with mixed features among patients with alcohol use disorder.

Authors:  Francesco Oliva; Maurizio Coppola; Raffaella Mondola; Daniele Ascheri; Francesco Cuniberti; Gabriele Nibbio; Rocco Luigi Picci
Journal:  BMC Psychiatry       Date:  2017-05-12       Impact factor: 3.630

7.  The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder.

Authors:  Konstantinos N Fountoulakis; Lakshmi N Yatham; Heinz Grunze; Eduard Vieta; Allan H Young; Pierre Blier; Mauricio Tohen; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2020-04-23       Impact factor: 5.176

8.  Neuromodulation therapies and treatment-resistant depression.

Authors:  Khalid Saad Al-Harbi; Naseem Akhtar Qureshi
Journal:  Med Devices (Auckl)       Date:  2012-07-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.